Home
Contact
Careers
Terms and Conditions
Privacy Policy
About Arcturus
RNA Medicines
Technologies
Pipeline
Patients and Family
Business Development
Publications
Investor Relations
Arcturus Reports Strong Three-Month Durability Results from ARCT-154 Booster Trial
May 5, 2022